Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Keratosis, Actinic 9Uterine Cervical Dysplasia 3Melanoma 3Breast Neoplasms 3Squamous Intraepithelial Lesions 2Papillomavirus Infections 2HIV Infections 2Condylomata Acuminata 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Squamous Cell Carcinoma of Head and Neck 1Sexually Transmitted Diseases 1Pigmentation Disorders 1Neoplasms 1Keratosis 1Hemangioma, Capillary 1Glioblastoma 1Breast Neoplasms, Male 1Anus Neoplasms 1Acquired Immunodeficiency Syndrome 1

Interventions

Temozolomide 115Bevacizumab 72Radiotherapy 52Radiation 23Erlotinib Hydrochloride 13Lomustine 12pembrolizumab 11Magnetic Resonance Spectroscopy 11Vorinostat 10Nivolumab 10Surgical Procedures, Operative 9Irinotecan 9Sorafenib 8Radiotherapy, Intensity-Modulated 8Radiotherapy, Conformal 7Immunoglobulin G 7Everolimus 7Drug Therapy 7Disulfides 7Radiosurgery 6Granulocyte-Macrophage Colony-Stimulating Factor 6Carmustine 6antineoplaston AS 2-1 5antineoplaston A10 5Sirolimus 5Cilengitide 5veliparib 4veledimex 4temsirolimus 4selinexor 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Glioblastoma × Imiquimod × Clear all
NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Stemline Therapeutics, Inc.

Phase 1/2 Completed
74 enrolled 19 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡